Company intelligence / Profile preview
Cue Biopharma
Boston, Massachusetts, United Statescuebiopharma.com ↗
- Ownership
- Public · CUE
- Development stage
- Phase 1
01
Overview
Cue Biopharma has developed a proprietary platform to engineer biologics that selectively engage and modulate disease-specific T cells within the patient’s body. Their approach aims to harness the immune system with greater specificity and safety than traditional immune-modulating drugs. The company’s lead programs are in clinical development targeting cancer and autoimmune diseases.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Engineered biologics (injectable)T cell engagers
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Boehringer Ingelheim (for next-generation treatment of autoimmune and inflammatory diseases)
04
Financials
- Market cap
- $130.8M
- Total revenue
- $27.5M
- Enterprise value
- $122.2M
Beyond the preview
Go deeper on Cue Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cue Biopharma.